Two open day events about the proposed Broadmoor Hospital Redevelopment will be held in Crowthorne Village on Monday 5 September and Thursday 8 September 2011.
Each event will offer local people the opportunity to hear more about our proposals to redevelop the site and give their views.
Redevelopment professional from both the design and service areas will be in attendance, to give visitors a good overview of the external alterations and internal effects of the proposed redevelopment.
Find out about our plans to become a Foundation Trust and improve your local mental health services.
Music and short films will accompany presentations and an opportunity to put questions to the Board.
Ealing Town Hall
New Broadway
Ealing
W5 2BY
21 September
12.30pm – lunch
1.30pm – Annual general meeting
1. Opening and Welcome
2. Apologies for absence
3. Declaration of interests
4. Minutes of the previous meeting held on 27th July 2011
5. Matters arising – Board Action Schedule
6. Chairman’s report and Board visit feedback
8. Research and Development 5 Year Strategy Progress – Stage 1 projects
9. Integrated Performance report – month 4 July 2011
11a. Trust Management Team meeting 13th July 2011
This study aims to test the effectiveness and safety of a new compound compared to placebo and donepezil, in those with mild and moderate Alzheimer’s disease.
A multicentre experimental medicine study that will evaluate whether there are detectable increases in blood brain barrier (BBB) permeability in patients with dementia.
Dynamic dadolinium (Gd) contrast-enhanced magnetic resonance imaging (MRI) will be used to text for increased BBB permeability in patients with mild to moderate dementia in comparison with controls.
The PALMFlexS study aims to evaluate how effective and safe paliperidone palmitate in patients with schizophrenia who have been unsuccessfully treated with oral or LIA anti-psychotic medications.
Participants receive an intramuscular injection once a month for six months.
This study is open to partipants.
This study is being done to investigate the safety, tolerability and effectiveness of two different daily doses of an investigational medication, tideglusib, in patients with mild to moderate Alzheimer’s disease.
This study lasts for 26 weeks and patients are treated at the West London Cognitive Disorders Treatment & Research Unit at Brentford Lodge.
The study is open to participants.
EVIDEM-E is a randomised, controlled evaluation of exercise therapy and its impact on behaviour, sleep and quality of life.
This study will test whether going for regular walks can improve sleep, behviour and life in general. It will also be looking at the impact on medication use and quality of life for both the individuals with dementia and their carers.
Our public consultation on becoming a Foundation Trust began on 8 July and continues until 27 October. We have held a public consultation event in Ealing and will be holding public consultation events in Hounslow, Broadmoor Hospital and Hammersmith and Fulham, as part of our Board meetings. (The regular Board meeting will follow after a 30 minute break, at 1pm.)
Chief Executive, Peter Cubbon, will be leading these events, so please get along to one to find out more about our plans; how to stand for election as a governor, and why achieving FT status will help us all thrive.
Date and time:
Wednesday 24 August, 11.30am to 12.30pm (Board meetings starts at 1pm)
Location:
O Block
Lakeside Mental Health Unit
Twickenham Road
Isleworth
TW7 6AF
Map (Opens in a new window)
You can also read the consultation document online, as well as fill in an online feedback form here.
More info: ft@wlmht.nhs.uk or 020 8354 8325
The BRIDGE study, which looked at more than 5,500 people diagnosed with major depression around the world, found that the less-commonly-used ‘bipolar specifier’ diagnosed 30% more people with bipolar disorder than the standard tool.
A misdiagnosis of bipolar disorder as depression may lead to ineffective treatment with antidepressants without the use of mood stabilisers – a key drug treatment for the disorder.
The benefits of antidepressants in bipolar disorder are thought to be modest at best, and treatment that is based solely on anti-depressants may have adverse consequences.
Prof Allan Young from West London Mental Health Trust, lead investigator in the UK, said: “The outcomes of this study could be life-changing for people who may have been misdiagnosed for years. Clinicians should investigate patients who present with depression carefully before they make a decision to prescribe anti-depressants.”
The key message of the study is clear: improved detection of bipolar disorder is relatively simple with newer screening tools and could lead to significantly improved outcomes for people with underlying, but unrecognised, bipolar disorder.
The most commonly used diagnostic tool used to detect bipolar disorder is called DSM-IV-TR. Bipolar disorders are narrowly diagnosed using this tool and doctors have long suspected that they are not optimal. The “Bipolar Specifier” was developed by Professor Angst and colleagues and seems to be more likely to detect bipolar disorder than DSM and, importantly, has low rates of over-diagnosis.
BRIDGE stands for Bipolar Disorders: Improving Diagnosis, Guidance and Education. The study arose from the BRIDGE initiative and was both multi-national and transcultural. It took place in community and hospital settings, looking at 5,635 patients with an ongoing major depressive episode.
Major depressive disorder is the most common psychiatric illness and is often experienced over many years.
Professor Allan Young is the clinical lead for the Affective Disorders service at West London Mental Health NHS Trust. He is also Chair of Psychiatry at Imperial College London. His interests are in the causes and treatment of severe neuro-psychiatric disorders, particularly affective disorders.